Medline (MDLN)

Medline (MDLN-Q) has shown a remarkable performance since its IPO, gaining 39.4% within the first month of trading. Although it is down from its peak, the stock demonstrates resilience compared to many IPOs from the previous year. The company reported solid financials, including a 9.8% net sales growth and a 12.9% adjusted EBITDA margin during the first nine months of 2025. Despite a healthy revenue growth trajectory, the balance sheet is considered decent but not exceptional. A noteworthy consideration for potential investors is that existing shareholders will retain 80% of voting power, limiting influence for new investors. The current trading valuation of approximately 45 times the earnings is perceived as steep for the company’s low double-digit growth projections, with a recommendation to consider buying at a lower price range of $29 to $30.